EUVIMEDEUVIMED entdecken
Crossref

A PHASE III, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTERED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBINATION THERAPY OF BOSWELLIA CURCUMIN AND JOINT AID PLUS IN SUBJECTS WITH JOINT PAIN

Vikram Chauhan

International Journal of Research in Ayurveda and Pharmacy · 30.10.2026 · 17 (5) · 90-96

DOI: 10.7897/2277-4343.175178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Research in Ayurveda and Pharmacy, online erschienen am 30.10.2026. Verfasst von Vikram Chauhan.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Joint pain, particularly associated with osteoarthritis (OA), is a leading cause of disability and reduced quality of life globally. Planet Ayurveda developed the combination therapy of Boswellia Curcumin and Joint Aid Plus to support joint health, alleviate pain, and improve physical function and quality of life.

Objective

To evaluate the efficacy and safety of the combination therapy of Boswellia Curcumin and Joint Aid Plus in participants diagnosed with knee osteoarthritis-associated joint pain. Materials and Methods: A Phase III, prospective, open-label, single-arm, single-centre study was conducted in participants with knee osteoarthritis-associated joint pain. Participants were instructed to use Boswellia Curcumin and Joint Aid Plus for 90 days. The primary objective was to assess change in total WOMAC score. Secondary objectives included assessment of VAS for pain, SF-36 for quality of life, safety, and tolerability.

Results

Out of 60 participants, 58 completed the study. The combination therapy demonstrated a progressive improvement in joint pain and functional outcomes over the 90-day treatment period. The mean total WOMAC score decreased from 38.16±4.66 at baseline to 22.31±3.82 at Day 90, while the mean VAS score decreased from 6.55±0.95 to 4.70±0.65. The mean SF-36 score improved from 80.82 at baseline to 99.83 at Day 90. The treatment was well tolerated, with no serious adverse events reported; reported adverse events were mild and transient. Overall compliance was 96.7%.

Conclusion

The combination therapy of Boswellia Curcumin and Joint Aid Plus demonstrated favourable effects on joint pain, osteoarthritis symptoms, and quality of life, with a favourable safety and tolerability profile.

Zitieren

APA

Chauhan, V. (2026). A PHASE III, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTERED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBINATION THERAPY OF BOSWELLIA CURCUMIN AND JOINT AID PLUS IN SUBJECTS WITH JOINT PAIN. International Journal of Research in Ayurveda and Pharmacy, 17(5), 90-96. https://doi.org/10.7897/2277-4343.175178

Vancouver

Chauhan V. A PHASE III, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTERED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBINATION THERAPY OF BOSWELLIA CURCUMIN AND JOINT AID PLUS IN SUBJECTS WITH JOINT PAIN. International Journal of Research in Ayurveda and Pharmacy. 2026;17(5):90-96. doi:10.7897/2277-4343.175178

BibTeX
@article{Chauhan2026,
  author = {Chauhan, Vikram},
  title = {A PHASE III, OPEN-LABEL, SINGLE-ARM, SINGLE-CENTERED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF COMBINATION THERAPY OF BOSWELLIA CURCUMIN AND JOINT AID PLUS IN SUBJECTS WITH JOINT PAIN},
  journal = {International Journal of Research in Ayurveda and Pharmacy},
  year = {2026},
  volume = {17},
  number = {5},
  pages = {90--96},
  doi = {10.7897/2277-4343.175178}
}
Kostenlos starten →